|
Dimethyl sulfoxide
|
1986
|
Cutaneous manifestations of scleroderma
|
|
Guanethidine monosulfate
|
1986
|
Moderate to severe reflex sympathetic dystrophy and causalgia
|
|
Bromhexine
|
1989
|
Mild to moderate keratoconjunctivitis sicca in patients with Sjögren’s syndrome
|
|
Immune globulin intravenous (human)
|
1992
|
Juvenile rheumatoid arthritis
|
|
Immune globulin intravenous (human)
|
1992
|
Polymyositis/dermatomyositis
|
|
AI-RSA
|
1992
|
Autoimmune uveitis
|
|
Methotrexate
|
1993
|
Juvenile rheumatoid arthritis
|
|
Dehydroepiandrosterone
|
1994
|
Systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients
|
|
Interferon beta-1a
|
1998
|
Juvenile rheumatoid arthritis
|
|
Humanized MAb (IDEC-131) to CD40L
|
1999
|
Systemic lupus erythematosus
|
|
Etanercept
|
1999
|
Wegener’s granulomatosis
|
|
pVGI.1 (VEGF2)
|
1999
|
Thromboangiitis obliterans
|
|
Infliximab
|
2003
|
Giant cell arteritis
|
|
Human Anti-tumor Necrosis factor alpha monoclonal antibody
|
2003
|
Uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy
|
|
Golimumab
|
2004
|
Chronic sarcoidosis
|
